oncothyreon inc (ONTY:NASDAQ GS)

Executive Profile*

Background*

Dr. Robert L. Kirkman, MD has been the Chief Executive Officer and President of Oncothyreon Inc. (alternate name Biomira Inc) since September 5, 2006. Dr. Kirkman served as an Acting President and Acting Chief Executive Officer of Xcyte Therapies Inc., from July 2005 to 2006. He served as Chief Business Officer and Vice President of Xcyte Therapies Inc., from February 16, 2004 to July 2005. He served as Chief Executive Officer of Xcyte Therapies Inc. He served as Chief ... Executive Officer and President at Cyclacel Pharmaceuticals, Inc. Dr. Kirkman has over 20 years of combined experience as a Business Development Officer in the Biotechnology world and as a practicing transplant surgeon. He served as Vice President for Business Development and Corporate Communications of PDL BioPharma, Inc. (formerly Protein Design Labs Inc.,) where he was responsible for business development, corporate finance and corporate communications, from July 1998 to 2003. Dr. Kirkman served as the Chief of the Division of Transplantation at Brigham and Women's Hospital from 1992 to 1998. He served in a position of Associate Professor for Surgery at Harvard Medical School from 1987 to 1998 and an Associate in Surgery at Massachusetts General Hospital from 1995 to 1998. He has been Executive Director of Oncothyreon Inc., since September 5, 2006. Dr. Kirkman is a Fellow of the American College of Surgeons. He holds an M.D. from Harvard Medical School and received his Post-Graduate Training at Peter Bent Brigham Hospital and Brigham and Women's Hospital and a B.A. in Economics from the Yale University.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
ONTY:US	$1.99 USD	+0.02

COMPETITOR COMPENSATION